Summary Thallium-201 single-photon emission computerized tomography (SPECT) was used to clarify the relationship between 201TI uptake and the response in chemotherapy to platinum compounds in 21 patients with small-cell lung cancer. 201TI-SPECT scans were obtained twice: at 15 min (early scan) and 120 min (delayed scan) after an intravenous injection of 111 MBq (3 mCi) of thallium-201 chloride. We obtained the uptake ratio from each scan and calculated the retention index:uptake ratio = region of interest uptake / contralateral normal lung uptake; retention index = (delayed ratio -early ratio)/early ratio. After 201TI scintigraphy, 12 patients received chemotherapy consisting of platinum compounds and nine were treated with chemoradiation. Among patients receiving only chemotherapy, the retention index correlated with the responses to chemotherapy. In an in vitro study, ouabain, an inhibitor of the Na,K-ATPase pump, reduced sensitivity to cisplatin and inhibited intracellular thallium uptake in the small-cell lung cancer cell line. These studies suggest that 201TI-SPECT is a useful indicator of response to chemotherapy with platinum compounds in small-cell lung cancer, and that Na,K-ATPase is commonly involved in transporting both thallium and platinum compounds into cancer cells.
Cisplatin (CDDP) is a useful anti-cancer agent, particularly when used in the treatment of human ovarian, testicular, bladder and small-cell lung cancer (Loehrer et al, 1984; Ohmori et al, 1993) . Many studies on cisplatin resistance mechanisms have revealed that the decline in intracellular accumulation of cisplatin is important in carcinoma cell lines (Hromas et al, 1987; Kraker and Moore, 1988; Andrews and Howell, 1990; Mann et al, 1990) . Cisplatin accumulation in these cells is reported to be regulated by an alteration in their Na,K-ATPase levels (Kawai et al, 1987; Andrews et al, 1991; Ohmori et al, 1993) . Thus, the response to chemotherapy with cisplatin might depend on alterations of Na,K-ATPase. scintigraphy is now used to diagnose myocardial infarction (Strauss et al, 1975) , myocardial ischaemia (Strauss and Boucher, 1986 ) and thyroid tumour (Bleichrodt et al, 1987; Charkes et al, 1990) . Recently, 207T1 single-photon emission computerized tomography (SPECT) was reported as being used to detect lung lesion (Tonami et al, 1989) , and it is reportedly superior to gallium scintigraphy in detecting lung cancer (Itoh et al, 1992 ; Matsuno et al, 1992) . Some studies demonstrated that TI accumulation in 201T1 scintigraphy is closely related to the Na,K-ATPase levels in malignant tumours (Britten and Blank, 1968; Muranaka, 1981; Kishida, 1987; Sehweil et al, 1989 ). And we reported that the delayed ratio is related to low levels of Na,K-ATPase activity (Takekawa et al, 1996) .
We hypothesized that the degree of TI uptake to tumour in 201Tl scintigraphy is associated with the response to chemotherapy with platinum compounds that have uptake mechanisms similar to TI. To clarify the relationship between TI uptake and the response to chemotherapy with platinum compounds, we examined patients with small-cell lung cancers. Furthermore, we studied in vitro the effect of pretreatment with ouabain, a Na,K-ATPase inhibitor, on the amount of intracellular TI uptake and the change in sensitivity to CDDP to clarify the relationship between intracellular thallium uptake and sensitivity to cisplatin in the small-cell lung cancer cell line (Ohmori et al, 1993 (Ohmori et al, , 1994 .
A new method for the assay of intracellular T1 accumulation was used: inductively coupled plasma mass spectrometry (ICP-MS). ICP-MS is analytical technique with high sensitivity for the determination of trace elements in biological samples. The ICP-MS has several advantages for trace elements determination: simultaneous multielements determination; ultrasensitive detection; wide dynamic range (Mauras et al, 1993; Yoshinaga et al, 1993) .
MATERIALS AND METHODS Patients
We studied 25 new patients who had small-cell lung carcinomas: they were examined by 201TI-SPECT in our hospital from 1991 to 1996. They had received no previous chemotherapy or radiation therapy. Diagnosis was made by the cytology of the endoscopic sampling method (catheter biopsy, bronchoalveolar lavage) and/or histopathology of endoscopic forceps biopsy. We excluded four patients out of the 25: one patient whose primary nodule was too small (less than 15 mm in minor axis) for the sensitivity of 201T1-SPECT in lung cancers (Tonami et al, 1989) (1988) reported that 201T1 uptake occurs rapidly in tumours, with peak values obtained 10-15 min post-injection in most cases, and there were no significant changes in tumour-background ratio between the 1 h post-injection image and 4 h post-injection image. Furthermore, we have previously reported that 207T1-SPECT scanning at 120 min is associated with the Na,K-ATPase level of the tumour (Takekawa et al, 1996) . Thus, 15 min and 120 min were thought to be suitable times to take images in 207T1-SPECT. A gamma-camera (GE-Maxi 400 AT/C) equipped with a parallel-hole collimator was interfaced with a detection computer (Starcom II). Focusing on the chest, the detector was rotated in stages of approximately 60 for a total of 3600. Transaxial images were reconstructed with a Hanning pre-filter and a Ramp post-filter. Coronal and sagittal section images were assembled from transaxial images (Itoh et al, 1992; Takekawa et al, 1994; Takekawa et al, 1996) . Without prior knowledge of the cytological or pathological findings, all of the images were interpreted for the presence or absence of abnormal accumulations at a conference of nuclear medicine specialists. When the 201T1-SPECT scan showed an abnormal uptake in a lesion, regions of interest (ROTs) were determined and established in both the area with abnormal radioactivity and the contralateral normal lung on the coronal sections of both the early and delayed scans. The mean voxel counts for the ROIs were measured and the uptake ratios of the lesion to the contralateral normal lung were calculated for both the early and delayed scans. We calculated the retention index (Tonami et al, 1989; Takekawa et al, 1994) to quantitatively evaluate the degree of 20711 retention in the nodule:retention index = (delayed ratio -early ratio)/early ratio.
Treatment
Protocol was decided by lung cancer treatment committees according to the patient's performance status, renal function, respiratory function, cardiac condition, liver function and peripheral blood cell counts. In general, treatment was as powerful as the patients could bear. After T1 scintigraphy, patients received combination chemotherapy: CDDP 80 mg m--2on day 1 and etoposide 100 mg m-2 on days 1, 3 and 5 or carboplatin (CBDCA) 300-600 mg on day 1 and etoposide 100 mg m-2 on days 1, 3 and 5. Carboplatin dosage was determined according to Calvert's formula (Calvert et al, 1989) .
Thoracic radiation therapy consisting of 50-60 Gy in 20-24 fractions over 5-6 weeks was simultaneously used with chemotherapy in LD patients who had good respiratory function, good performance status and no interstitial pneumonitis on chest radiography or computerized tomography. When the ED patients had brain metastasis or painful bone metastasis, metastatic sites were simultaneously treated with radiation therapy. The chemotherapy group was defined as those treated with chemotherapy only, and the chemoradiation group was defined as the patients treated with both chemotherapy and radiation therapy at any site. Chemotherapy was repeated for at least two courses; in cases of partial response or complete response, as mentioned below, chemotherapy was repeated every 4 weeks until the time it was determined the tumour would not decrease in volume. At that point, in cases of no change or progressive disease, we chose palliative therapy for better quality of life of the patient.
Response criteria
In chemotherapy, response evaluation was performed using traditional criteria: a complete response (CR) was defined as the disappearance of all evidence of disease for 4 weeks; a partial response (PR) was defined as a 50% or greater reduction in the sum of the product of the two greatest perpendicular diameters of all measurable lesions for more than 4 weeks, without the appearance of new lesions or the progression of any lesion; no change (NC) was defined as a less than 50% decrease or a less than 25% increase in the sum of the product of the two greatest perpendicular diameters of lesions with no new lesions; and progressive disease (PD) was defined as a 25% or more increase in the size of one or more lesions, or the appearance of new lesions. A good response was defined as CR or PR, and the response rate (%) was defined as good response patients/all patients x 100.
Drugs and chemicals Thallium was purchased from Wako Chemical (Osaka, Japan); CDDP and ouabain were purchased from Sigma Chemical (St Louis, MO, USA); RPMI-1640 was purchased from Nissui Pharmaceutical (Tokyo, Japan).
Cell line
Human small-cell lung cancer cell line PC-6 was obtained from the Japanese Cancer Research Resources Bank (Tokyo, Japan). This cell line was cultivated in tissue culture flasks (Falcon) in RPMI-1640 medium with 10% fetal bovine serum, 100 units ml-1 penicillin and 100 gg ml-' streptomycin.
Thallium accumulation test PC-6 cells (1 x 106) were preincubated in 10 cm tissue culture plates (Falcon 3003) overnight. Ouabain (200 gM) was added to the cells and they were incubated for 1 h (subsequently, PC-6/O), after which the medium was fully vacuumed. An aliquot (10 ml) of RPMI-1640 containing 10 p.p.m. thallium was added to cells for 10 min, followed by two washes with phosphate-buffered saline (PBS). A 1-ml sample of 0.9% sodium chloride was added, and cells were harvested by scraping and then transferred to plastic tubes. Next, 1 ml of 100% nitric acid was added to the tubes and the solutions were taken up into Teflon resolution vessels (Flon Industry, Tokyo, Japan). The vessels were placed in a vacuum oven and heated for 2 h. After cooling, the samples were diluted to 10 ml with Millipore MiliQ water.
For control PC-6, the same procedures were used, but no ouabain was added.
British Journal of Cancer (1998) 77(8), [1363] [1364] [1365] [1366] [1367] [1368] . Cancer Research Campaign 1998 Predicting chemotherapeutic response by 01 TI SPECT 1365 Drug sensitivity test Chemosensitivity of the cells to CDDP was determined using the XTT assay, as previously reported (Scudiero et al, 1988; Kondo et al, 1994) . After preincubation at 37°C overnight, the 200 gM ouabain was added to PC-6 (now, PC-6/O), incubated for 1 h at 37'C and washed twice with PBS. Various concentrations of the CDDP were added to PC-6 and PC-6/0, and all cells were incubated for 1 h and washed twice with PBS. Units of 1000 cells were seeded into 96-well microplates and incubated at 37°C for 96 h. After incubation, 50,g of 2,3-bis (2-methoxy-4-nitro-5-sulphophenyl) [(phenyl-amino) carbonyl]-2H-tetrazolium hydroxide (XTT, Sigma, St Louis, MO, USA) with 0.38 ,ug of phenazine methosulphate (PMS, Sigma) were added to each well and incubated at 37°C for 4 h. The plates were agitated on a plate shaker for 5 min, and the absorbance was measured at 450 nm using an ELISA reader. The drug concentration producing 50% inhibition of growth (IC50) was determined from a standard concentration-response curve. Each experiment was repeated three times.
Statistics
In clinical study, between-group comparisons were carried out using the Mann-Whitney U-test. Differences were considered significant when the P-value was less than 0.05. In an in vitro study, comparisons between means of thallium accumulation and IC50 on CDDP sensitivity test were performed using Student's t-test. Differences were considered significant when the P-value was less than 0.05.
RESULTS
The characteristics of the 12 patients treated with only chemotherapy are listed in Table 1 , and the characteristics of the nine patients treated with chemoradiation therapy are listed in Table 2 . The overall response rate was 62%; CR rate was 33% of the 21 patients. Figure 1 shows that the retention indexes for the PR and the CR groups were significantly higher than those of the PD and the NC groups among patients treated only with chemotherapy (P = 0.012). Except for CBDCA patients, the difference is clear too (P = 0.025). This demonstrated that the retention index was a reliable indicator for chemotherapy among patients with small-cell lung carcinomas. However, if we consider all data in both Tables 1  and 2 , the difference between them is not clear (P = 0.075): combining radiation therapy with chemotherapy might overcome the relationship between the retention index and the effect of chemotherapy. Considering only the patients who did not receive thoracic radiation (numbers 2, 4, 6, 7 in Table 2) in Table 1 , the difference was statistically consistent (P = 0.043).
In contrast, the early ratio and the delayed ratio showed no association with chemotherapeutic response among these patients (data not shown). Figure 2 shows the standard curve for thallium determination by ICP-MS. The correlation coefficient of the regression line was 0.999. ICP-MS is an analytic technique with high sensitivity, and the standard curve has a wide linear range in measuring Ti concentration, as previously reported (Yoshinaga, et al, 1993; Mauras et al, 1993) .
Intracellular thallium uptake is demonstrated in PC-6 and PC-6/0, as ouabain-treated PC-6 cells, in Figure 3 . The level of intracellular thallium in PC-6/O is clearly lower than in PC-6 after contact with thallium. We obtained the same result with successive experiments: Ouabain reduced intracellular thallium uptake in the PC-6 cell line. Figure 4 shows the result of the cisplatin sensitivity test. PC-6/0 was pretreated with ouabain and showed less response to CDDP than did PC-6. The IC50 for PC-6 was 3.1 gm; for PC-6/O, 5.1 gM. There is a significant difference between them (P < 0.05), demonstrating that ouabaine reduced sensitivity to CDDP in the PC-6 cell line.
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Thallium-201 chloride has been described as a positive indicator for lung cancer (Cox et al, 1976; Salvatore et al, 1976; Tonami et al, 0o 1976) . SPECT provides a significant improvement, with respect to the radiopharmaceutical distribution in the body in three dimensions 0o and the ability to extract true quantitative values from structures deep within the body (Matsuno et al, 1992; Yokoi et al, 1994) . 0o 207T1-SPECT has been reported to visualize lung cancers as small as 1.5 x 1.0 cm (Tonami, et al, 1989) , and 1.0 x 1.0 cm (Matsuno et al, t0 1992) . It is possible to diagnose a lung tumour larger than 15 mm in diameter as benign or malignant (Tonami et al, 1989) .
The accumulation patterns of 207T1 on early and delayed scans differ between benign and malignant lung and thyroid tumours TI concentration (p.p.b.) (Ochi et al, 1982; Tonami et al, 1989; El-desouki 1991) . show accumulation of 201TI on both the early and the delayed scans. Retention of 201TI on the delayed scan is strongly suggestive of malignancy. In rats, the 201T1 accumulation revealed in inflammatory lesions decreased with time, but 201TI washout from malignant tumours tended to be delayed (Ando et al, 1987) . In 201TI scintigraphy, the early ratio in a tumour reflects vascularity (Taguchi 1992 ) and blood pooling (Caluser et al, 1992) , whereas the delayed ratio reflects the cell's ability to increase TIINa,K-ATP levels (Ando et al, 1988; Caluser et al, 1992; Takekawa et al, 1996) as well as the viability of tumour cells (Mountz, et al 1989; Sehweil et al, 1989) . The retention index was defined thus: retention index = (delayed ratio -early ratio)/early ratio. Defining the early ratio as vascularity and the delayed ratio as Na,K-ATPase, this formula would mean that Na,K-ATPase varied with vascularity. Therefore, the retention index would be a stronger indicator of active transportation by Na,K-ATPase into cancer cells in the body than would the delayed ratio by itself.
In an in vitro study, influx of thallium into malignant cells is regulated by its active transportation by Na,K-ATPase (Muranaka, 1981;  Kishida, 1987; Sehweil et al, 1989 ). Since we showed that the Na,K-ATPase inhibitor ouabain blocks intracellular thallium uptake in the PC-6 cell line, Na,K-ATPase must play a vital role in intracellular thallium uptake.
In this study, the retention index of 201TI-SPECT was associated with the response to chemotherapy with platinum compounds in small-cell lung carcinomas. Therefore, the retention index might be an indicator of response to chemotherapy with platinum compounds in small-cell lung carcinomas. Although chemotherapy with platinum compounds has potency in small-cell lung cancers, especially in combination with etoposide (Seifter and Ihde, 1988) , the responses vary from complete recovery to progression of the disease. Cisplatin accumulation in these cells is probably regulated by an alteration in their Na,KATPase levels (Kishida, 1987; Andrews et al, 1991; Ohmori et al, 1993) . Many cisplatin-resistant cell lines show cross-resistance to carboplatin (Kraker et al, 1988; Ohmori et al, 1993) . Ohmori reported that PC-14/CDDP, a cisplatin-resistant non-small-cell lung cancer cell line, showed 3.5-fold resistance to carboplatin, and that the accumulation of cisplatin and carboplatin decreased to 23% and 27%. In addition, ouabain inhibited 60% of CDDP accumulation in PC-14, whereas the same dose of ouabain did not affect CDDP accumulation in PC-14/CDDP (Ohmori et al, 1993) . Thus, carboplatin may behave similarly to cisplatin on drug-resistant mechanisms. With or without carboplatin groups, there was no difference in this clinical study in the relationship between 207T1 accumulation and the chemotherapy effect.
Our in vitro study suggested that the sensitivity to CDDP might be associated with the intracellular uptake of thallium by alterations in Na,K-ATPase in the small-cell lung cancer cell line. In addition, the accumulation in cancer cells of thallium and platinum compounds might be regulated by a common mechanism: active transportation by Na,K-ATPase. Together, these indicated that the accumulation shown in the tumour in 201Tl-SPECT correlated with that of the platinum compounds. To our knowledge, this is the first report demonstrating a significant relationship between the uptake ratios of 207T1-SPECT and the prediction of chemoresponse to platinum compounds.
Because we used the standard treatment for small-cell lung cancer patients in this clinical study, i.e. combination chemotherapy with platinum compounds and etoposide, we cannot disregard etoposide effects. Therefore, other studies might be needed to determine the effects of etoposide.
Recently rubidium-82 (82Rb) and positron emission tomography (PET) have been used to diagnose myocardial infarction (Goldstein et al, 1986 ). Because 82Rb is taken up into cells by Na,K-ATPase in the same way as 207T1 -and as PET gives more accurate images than 207T1 SPECT -a follow-up study using 82Rb and PET might clarify the relationship between uptake and chemotherapeutic response.
The benefit of 207T1-SPECT is its non-invasiveness: 207T1-SPECT can give a safe, reliable prediction on a patient's response to chemotherapy. If we can predict the response, we can avoid ineffective chemotherapy and unfavourable toxicity, and choose more suitable drugs for lung cancer patients.
In conclusion, 207T1-SPECT could be a useful indicator of response to chemotherapy with platinum compounds in lung cancers.
